Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors.

The company is headquartered in Boulder, Colorado.

Enliven Therapeutics, Inc.

Country	United States
Founded	2016
IPO Date	Mar 12, 2020
Industry	Biotechnology
Sector	Healthcare
Employees	62
CEO	Richard Fair

Contact Details

Address: 6200 Lookout Road Boulder, Colorado 80301 United States
Phone	720 647 8519
Website	enliventherapeutics.com

Stock Details

Ticker Symbol	ELVN
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$16.00
CIK Code	1672619
CUSIP Number	29337E102
ISIN Number	US29337E1029
Employer ID	81-1523849
SIC Code	2834

Key Executives

Name	Position
Richard A. Fair	Chief Executive Officer, President and Director
Samuel S. Kintz M.B.A.	Co-Founder and Head of Pipeline
Dr. Joseph P. Lyssikatos Ph.D.	Co-Founder and Chief Scientific Officer
Dr. Helen Louise Collins M.D.	Chief Medical Officer
Anish Patel Pharm.D.	Co-Founder and Chief Operating Officer
Benjamin Hohl	Chief Financial Officer and Head of Corporate Development
Dr. Galya D. Blachman Esq., Ph.D.	Chief Legal Officer and Head of Business Development

Latest SEC Filings

Date	Type	Title
Jan 9, 2026	144	Filing
Jan 9, 2026	144	Filing
Jan 9, 2026	144	Filing
Jan 8, 2026	144	Filing
Jan 8, 2026	144	Filing
Jan 8, 2026	144	Filing
Jan 8, 2026	144	Filing
Jan 7, 2026	8-K	Current Report
Dec 19, 2025	144	Filing
Dec 17, 2025	144	Filing

View All SEC Filings